Shares of Oxford Biomedica (NASDAQ:OXBDF) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Zacks has also given Oxford Biomedica an industry rank of 105 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research upgraded shares of Oxford Biomedica from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research note on Tuesday, July 11th.

TRADEMARK VIOLATION NOTICE: “Zacks: Oxford Biomedica (OXBDF) Receives Average Recommendation of “Strong Buy” from Analysts” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at

Oxford Biomedica (NASDAQ:OXBDF) traded up 0.000% on Friday, reaching $0.105. Oxford Biomedica has a 12-month low of $0.04 and a 12-month high of $0.06. The stock’s market capitalization is $319.20 million.

About Oxford Biomedica

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Get a free copy of the Zacks research report on Oxford Biomedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with's FREE daily email newsletter.